Literature DB >> 33466816

Alterations in Glucose Metabolism Due to Decreased Expression of Heterogeneous Nuclear Ribonucleoprotein M in Pancreatic Ductal Adenocarcinoma.

Jun-Ichi Takino1, Takuma Sato1, Isamu Hiraishi1, Kentaro Nagamine2, Takamitsu Hori1.   

Abstract

The prognosis of pancreatic cancer is considerably worse than that of other cancers, as early detection of pancreatic cancer is difficult and due to its hypovascular environment, which involves low blood flow and a low supply of oxygen and nutrients. Moreover, pancreatic cancer demonstrates a mechanism that allows it to survive in a hypovascular environment. However, the detailed mechanism remains elusive. Recently, it has been reported that heterogeneous ribonuclear protein M (HNRNPM) is a splicing factor associated with malignant tumors. Thus, in this study, we investigated the expression and effects of HNRNPM in pancreatic ductal adenocarcinoma (PDA). We observed that HNRNPM expression, which is highly expressed in pancreatic tissues, was reduced in PDA tissues. Additionally, knockdown of HNRNPM under low-glucose conditions that mimic a hypovascular environment was shown to alter glucose metabolism and prolong cell survival by suppressing glucose consumption. These results suggest that the decreased expression of HNRNPM in PDA may be involved in its adaptation to a hypovascular environment.

Entities:  

Keywords:  consumption; glucose; heterogeneous nuclear ribonucleoprotein M (HNRNPM); metabolism; pancreatic ductal adenocarcinoma (PDA)

Year:  2021        PMID: 33466816      PMCID: PMC7830884          DOI: 10.3390/biology10010057

Source DB:  PubMed          Journal:  Biology (Basel)        ISSN: 2079-7737


  26 in total

1.  Identification of HnRNP M as a novel biomarker for colorectal carcinoma by quantitative proteomics.

Authors:  Shuijiao Chen; Jie Zhang; Lunxi Duan; Yu Zhang; Cui Li; Deliang Liu; Chunhui Ouyang; Fanggen Lu; Xiaowei Liu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-12-31       Impact factor: 4.052

2.  Cellular energetics and the oxygen dependence of respiration in cardiac myocytes isolated from adult rat.

Authors:  W L Rumsey; C Schlosser; E M Nuutinen; M Robiolio; D F Wilson
Journal:  J Biol Chem       Date:  1990-09-15       Impact factor: 5.157

3.  Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.

Authors:  Mahsa Zarei; Shruti Lal; Seth J Parker; Avinoam Nevler; Ali Vaziri-Gohar; Katerina Dukleska; Nicole C Mambelli-Lisboa; Cynthia Moffat; Fernando F Blanco; Saswati N Chand; Masaya Jimbo; Joseph A Cozzitorto; Wei Jiang; Charles J Yeo; Eric R Londin; Erin L Seifert; Christian M Metallo; Jonathan R Brody; Jordan M Winter
Journal:  Cancer Res       Date:  2017-06-26       Impact factor: 12.701

4.  hnRNPM, a potential mediator of YY1 in promoting the epithelial-mesenchymal transition of prostate cancer cells.

Authors:  Tong Yang; Zesheng An; Changwen Zhang; Zhen Wang; Xiaoming Wang; Yan Liu; E Du; Ranlu Liu; Zhihong Zhang; Yong Xu
Journal:  Prostate       Date:  2019-08       Impact factor: 4.104

Review 5.  Targeting mitochondria metabolism for cancer therapy.

Authors:  Samuel E Weinberg; Navdeep S Chandel
Journal:  Nat Chem Biol       Date:  2015-01       Impact factor: 15.040

Review 6.  Pancreatic Cancer: Pathogenesis and Diagnosis.

Authors:  Vedat Goral
Journal:  Asian Pac J Cancer Prev       Date:  2015

Review 7.  New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.

Authors:  Ritu Raj Singh; Eileen M O'Reilly
Journal:  Drugs       Date:  2020-05       Impact factor: 9.546

8.  Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing.

Authors:  Yilin Xu; Xin D Gao; Jae-Hyung Lee; Huilin Huang; Haiyan Tan; Jaegyoon Ahn; Lauren M Reinke; Marcus E Peter; Yue Feng; David Gius; Kalliopi P Siziopikou; Junmin Peng; Xinshu Xiao; Chonghui Cheng
Journal:  Genes Dev       Date:  2014-05-19       Impact factor: 11.361

Review 9.  Metabolic Dependencies in Pancreatic Cancer.

Authors:  Ali Vaziri-Gohar; Mahsa Zarei; Jonathan R Brody; Jordan M Winter
Journal:  Front Oncol       Date:  2018-12-12       Impact factor: 6.244

10.  Poison-Exon Inclusion in DHX9 Reduces Its Expression and Sensitizes Ewing Sarcoma Cells to Chemotherapeutic Treatment.

Authors:  Ramona Palombo; Veronica Verdile; Maria Paola Paronetto
Journal:  Cells       Date:  2020-01-31       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.